公开(公告)号：EP3283619A1

公开(公告)日：2018-02-21

申请号：EP16720247.2

申请日：2016-04-15

申请人： Barrett, David Maxwell ,  Bedoya, Felipe ,  Ghassemi, Saba ,  June, Carl, H. ,  Levine, Bruce L. ,  Melenhorst, Jan J. ,  Milone, Michael C. ,  Powell, Daniel, J. ,  Singh, Nathan Amar ,  Zheng, Zoe

发明人： Barrett, David Maxwell ,  Bedoya, Felipe ,  Ghassemi, Saba ,  June, Carl, H. ,  Levine, Bruce L. ,  Melenhorst, Jan J. ,  Milone, Michael C. ,  Powell, Daniel, J. ,  Singh, Nathan Amar ,  Zheng, Zoe

IPC分类号： C12N5/0783 ,  C07K14/47 ,  C07K14/705 ,  C12N5/00 ,  A61K35/17

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K38/50 ,  A61K45/06 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/28 ,  C07K2317/622 ,  C07K2319/00 ,  C12N5/0636 ,  C12N2501/2302 ,  C12N2501/2305 ,  C12N2501/2307 ,  C12N2501/2318 ,  C12Y305/01001 ,  A61K2300/00

摘要： The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

公开(公告)号：EP3087101A4

公开(公告)日：2017-12-06

申请号：EP14872734

申请日：2014-12-19

申请人： NOVARTIS AG ,  UNIV PENNSYLVANIA ,  BROGDON JENNIFER ,  ENGELS BORIS ,  GLASS DAVID JONATHAN ,  GRANDA BRIAN ,  HASTEWELL JOHN ,  LOEW ANDREAS ,  MANNICK JOAN ,  MILONE MICHAEL C ,  MURPHY LEON ,  SELLERS WILLIAM RAJ ,  SONG HUIJUAN ,  VASH BRIAN EDWARD ,  WEILER JAN ,  WU QILONG ,  ZHOU LI

发明人： BROGDON JENNIFER ,  ENGELS BORIS ,  GLASS DAVID JONATHAN ,  GRANDA BRIAN ,  HASTEWELL JOHN ,  LOEW ANDREAS ,  MANNICK JOAN ,  MILONE MICHAEL ,  MURPHY LEON ,  SELLERS WILLIAM RAJ ,  SONG HUIJUAN ,  VASH BRIAN EDWARD ,  WEILER JAN ,  WU QILONG ,  ZHOU LI

IPC分类号： C07K19/00 ,  A61K31/436 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC分类号： C07K16/2863 ,  A61K31/436 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/71 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/41 ,  C07K2319/43 ,  C07K2319/70 ,  C12N9/1205 ,  C12N9/90 ,  C12Y502/00

摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：EP3623380A1

公开(公告)日：2020-03-18

申请号：EP19187938.6

申请日：2014-03-15

申请人： Milone, Michael C. ,  Wang, Enxiu

发明人： Milone, Michael C. ,  Wang, Enxiu

IPC分类号： C07K14/705 ,  C07K19/00

摘要： The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a "KIR-CAR" which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：EP3087101A1

公开(公告)日：2016-11-02

申请号：EP14872734.0

申请日：2014-12-19

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania ,  Brogdon, Jennifer ,  Engels, Boris ,  GLASS, David, Jonathan ,  GRANDA, Brian ,  HASTEWELL, John ,  LOEW, Andreas ,  MANNICK, Joan ,  Milone, Michael C. ,  MURPHY, Leon ,  SELLERS, William Raj ,  SONG, Huijuan ,  VASH, Brian Edward ,  WEILER, Jan ,  WU, Qilong ,  ZHOU, Li

发明人： BROGDON, Jennifer ,  ENGELS, Boris ,  GLASS, David Jonathan ,  GRANDA, Brian ,  HASTEWELL, John ,  LOEW, Andreas ,  MANNICK, Joan ,  MILONE, Michael ,  MURPHY, Leon ,  SELLERS,William Raj ,  SONG, Huijuan ,  VASH, Brian Edward ,  WEILER, Jan ,  WU, Qilong ,  ZHOU, Li

IPC分类号： C07K19/00 ,  C12N5/0783

CPC分类号： C07K16/2863 ,  A61K31/436 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/71 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/41 ,  C07K2319/43 ,  C07K2319/70 ,  C12N9/1205 ,  C12N9/90 ,  C12Y502/00

摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

摘要翻译： 提供了与可调节嵌合抗原受体（RCAR）相关的组合物和方法，其中可以控制RCAR的细胞内信号传导或增殖以优化使用表达RCAR的细胞以提供免疫应答。 例如，RCAR可以包含二聚转换开关，其在存在二聚化分子时可以将细胞内信号转导域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域或共刺激ECD结构域 。 RCAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。

公开(公告)号：EP2970426B1

公开(公告)日：2019-08-28

申请号：EP14722891.0

申请日：2014-03-15

申请人： Milone, Michael C. ,  Wang, Enxiu

发明人： Milone, Michael C. ,  Wang, Enxiu

IPC分类号： C07K14/705 ,  C07K19/00

公开(公告)号：EP2970426A2

公开(公告)日：2016-01-20

申请号：EP14722891.0

申请日：2014-03-15

申请人： Milone, Michael C. ,  Wang, Enxiu

发明人： Milone, Michael C. ,  Wang, Enxiu

IPC分类号： C07K14/705 ,  C07K19/00

CPC分类号： C07K16/18 ,  C07K14/70503 ,  C07K14/70535 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/70

摘要： The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

摘要翻译： 本发明提供调节T细胞的特异性和活性的组合物和方法。 在一个实施方案中，本发明提供了一种嵌合抗原受体（CAR），其中CAR被称为“KIR-CAR”，其是包含天然杀伤（NK）细胞天然存在的受体成分的CAR设计。 在一个实施方案中，NK受体包括但不限于称为杀伤细胞免疫球蛋白样受体（KIR）的NK细胞的天然存在的活化和抑制性受体。